Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received Class III medical device registration approval from the National Medical Products Administration on December 10, 2025 [1][3] - The collagen market in China has reached a scale of 200 billion, with projections to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high concentration of medical collagen at 45 mg/ml, ensuring strong support [5] - The product is made from high-purity bovine tendon collagen, which guarantees the integrity of the raw material [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper support for the skin [5] - The development team overcame several technical challenges, establishing 45 mg/ml as the optimal concentration to balance collagen network formation and safety [5] - The product maintains biological activity and structural integrity through meticulous production processes [5] Market Trends - The introduction of "Jiaoyuan Angel" is expected to shift the focus of collagen applications from immediate filling effects to a trend of nutritional tightening in the industry [7] - Yuansong Group has established a strong presence in the medical aesthetics sector with several successful products, positioning itself as a market leader [7] - Analysts predict that "Jiaoyuan Angel" could capture significant market share quickly, potentially becoming a dark horse in the medical aesthetics market by 2026 [7]

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received regulatory approval on December 10 [1][3] - The collagen market has reached a scale of 200 billion and is projected to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high medical collagen concentration of 45 mg/ml, ensuring strong support [5] - The product uses collagen extracted from bovine tendons, ensuring high purity and structural integrity [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper network support for the skin [5] - The company has addressed industry challenges, establishing 45 mg/ml as the optimal concentration to balance efficacy and safety [5] Market Positioning - The collaboration signifies an upgrade in the synergy between clinical institutions and research enterprises, aiming to redefine the application of collagen in the market [6] - The focus is shifting from "volume enhancement" to "nutritional tightening," which is expected to become the mainstream trend in the collagen market [8] - Yuansong Group has previously launched several successful products in the medical beauty sector, positioning itself as a market leader [8] - "Jiaoyuan Angel" is anticipated to capture significant market share and potentially become a dark horse in the medical beauty market by 2026 due to its technological advantages and promotional capabilities [8]

1月2日，全球首款源自牛跟腱的胶原蛋白产品将在媛颂全国直营体系首发。 同日，媛颂集团与崇山生物正式达成战略合作。媛颂集团CEO马伟伟表示，双方将产品与应用的技术优 势相结合，推动胶原领域从"体积增容"迈入"营养紧致"的全新阶段。其判断，未来胶原蛋白市场的应用 将被改写，营养紧致将成为行业主流趋势。 崇山生物董事长张智武表示，胶媛天使的高标准主要体现在三个经过重新定义的核心维度，在成分浓 度、材料来源、应用技术等方面具有优势。 此次媛颂集团与崇山生物的战略合作，标志着临床机构与研发企业协同模式的升级。马伟伟表示，公司 不只是引入一款新产品，而是以新品功能效果为基础，结合抗衰医学、自然美学、材料学，打造一套全 新的诊疗方案。 胶原蛋白在医疗、美容和保健等领域的应用推动市场快速增长，已形成2000亿的市场规模，预计2030年 将达5000亿。 作为全球首款牛跟腱胶原蛋白植入剂，崇山生物"娇媛天使"于去年12月10日获批国家药监局"械三证"。 随着娇媛天使"械三证"的落地，我国持械三证的胶原产品已增至15个，包括双美生物、斐缦生物、锦波 生物、巨子生物等知名企业，但真正上市成为主流的产品只占三分之一。 ...